Main Article Content
Abstract
Chronic kidney disease (CKD) is currently one of the most common diseases among chronic noncommunicable diseases. The progression of chronic kidney disease leads to the end-stage of the disease, which, in turn, is called end-stage renal failure and is characterized by a sharp decrease in the quality of life of patients, contributes to disability and disability, and also leads to the need to use expensive methods of renal replacement therapy: peritoneal dialysis, hemodialysis, kidney transplantation.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Yang CW, Harris DCH, Luyckx VA et al. Global case studies for chronic kidney disease/end-stage kidney disease care. Kidney Int Suppl. 2020; 10(1): e24-e48. doi: 10.1016/j.kisu.2019.11.010
Clinical guidelines «Treatment of patients with chronic stage 5 kidney disease (CKD 5) by hemodialysis and hemodiafiltration». Developer: Association of Nephrologists. Russian Dialysis Society. Metropolitan Association of Physicians Nephrologists. Approved: March 10, 2016. Russian (Клинические рекомендации «Лечение пациентов с хронической болезнью почек 5 стадии (ХБП 5) методами гемодиализа и гемодиафильтрации». Разработчик: Ассоциация Нефрологов. Российское Диализное Общество. Столичная Ассоциация Врачей Нефрологов. Утверждено: 10 марта 2016 г.)
Tomilina NA, Andrusev AM, Peregudova NG, Shinkarev MB. Replacement therapy for end-stage chronic renal failure. Report on the data of the All-Russian Register of Renal Replacement Therapy of the Russian Dialysis Society. Part one. Nephrology and Dialysis. 2017; 19(4, appendix): 1-95. Russian (Томилина Н.А., Андрусев А.М., Перегудова Н.Г., Шинкарев М.Б. Заместительная терапия терминальной хронической почечной недостаточности. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества. Часть первая //Нефрология и диализ. 2017; 19(4, приложение): 1-95)
Hansson JH and Watnick S. Update on Peritoneal Dialysis: Core Curriculum 2016. Am J Kidney Dis. 2016; 67(1): 151-164
Liyanage T, Ninomiya T, Jha V, Patrice HM, Okpechi I, Zhao M, et al. Worldwide access to treatment for end stage kidney disease: a systematic review. Lancet. 2015
See EJ, Jayasinghe K, Glassford N, et al. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int. 2019; 95(1): 160-172. doi: 10.1016/j.kint.2018.08.036
Hu MK, Witham MD, Soiza RL. Oral Bicarbonate Therapy in Non-Haemodialysis Dependent Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. J Clin Med. 2019; 8(2): 208. doi: 10.3390/jcm8020208
Shen Y, Cai R, Sun J et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine. 2017; 55(1): 66-76. doi: 7.1007/s12020-016-1014-6
Chang AR, Grams ME, Ballew SH et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2019; 364: k5301. doi: 10.1136/bmj.k5301
Rashidbeygi E, Safabakhsh M, Delshad Aghdam S et al. Metabolic syndrome and its components are related to a higher risk for albuminuria and proteinuria: Evidence from a meta-analysis on 10,603,067 subjects from 57 studies. Diabetes Metab Syndr. 2019; 13(1): 830-843. doi: 10.1016/j.dsx.2018.12.006
Mantovani A, Zaza G, Byrne CD et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2018; 79:.64-76. doi: 10.1016/j.metabol.2017.11.003
Yu X, Yuan Z, Lu H et al. Relationship between birth weight and chronic kidney disease: evidence from systematics review and two-sample Mendelian randomization analysis. Hum Mol Genet. 2020; 29(13): 2261-2274. doi: 13.1093/hmg/ddaa074
Major RW, Cheng MRI, Grant RA et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2018; 13(3): e0192895. doi: 10.1371/journal.pone.0192895
Alizadeh S, Esmaeili H, Alizadeh M et al. Metabolic phenotypes of obese, overweight, and normal weight individuals and risk of chronic kidney disease: a systematic review and meta-analysis. Arch Endocrinol Metab. 2019; 63(4): 427-437. doi: 10.20945/2359- 3997000000149
Schwasinger-Schmidt TE, Elhomsy G, Paull-Forney BG. Impact of a Community-Based Weight Loss Program on Renal Function. Cureus. 2020; 12(5): e8101. doi: 10.7759/cureus.8101
Bundy JD, Bazzano LA, Xie D, Cohan J et al. Self-Reported Tobacco, Alcohol, and Illicit Drug Use and Progression of Chronic Kidney Disease. Clin J Am Soc Nephrol. 2018; 13(7): 993-1001. doi: 10.2215/CJN.11121017
Coresh J, Heerspink HJL, Sang Y et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019; 7(2): 115-127. doi: 10.1016/S2213-8587(18)30313-9
Zheng Q, Yang H, Liu W et al. Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic 154 review and network meta-analysis. BMJ Open. 2019; 9(9): e030919. doi: 10.1136/bmjopen-2019-030919